Go Pro
→ The $15 Gold Fund That Pays Up to $1,152/Month (From Investors Alley) (Ad)tc pixel Free JSPRW Stock Alerts

Jasper Therapeutics (JSPRW) Competitors

Jasper Therapeutics logo
$0.0099 +0.00 (+6.49%)
As of 09/2/2026 03:59 PM Eastern
This is a fair market value price provided by Massive. Learn more.
Compare

JSPRW vs. ALVOW, APLMW, ARAV, BIAFW, and BIVIW

Should you buy Jasper Therapeutics stock or one of its competitors? Jasper Therapeutics's main competitors and comparable companies include Alvotech (ALVOW), Apollomics (APLMW), Aravive (ARAV), bioAffinity Technologies (BIAFW), and BioVie (BIVIW). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Jasper Therapeutics compare to Alvotech?

Jasper Therapeutics (NASDAQ:JSPRW) and Alvotech (NASDAQ:ALVOW) are both healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, valuation, analyst recommendations, media sentiment, profitability, earnings, dividends and risk.

In the previous week, Alvotech had 1 more articles in the media than Jasper Therapeutics. MarketBeat recorded 1 mentions for Alvotech and 0 mentions for Jasper Therapeutics. Alvotech's average media sentiment score of 0.92 beat Jasper Therapeutics' score of 0.00 indicating that Alvotech is being referred to more favorably in the news media.

Company Overall Sentiment
Jasper Therapeutics Neutral
Alvotech Positive

Company Net Margins Return on Equity Return on Assets
Jasper TherapeuticsN/A N/A N/A
Alvotech N/A N/A N/A

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Jasper TherapeuticsN/AN/AN/AN/AN/A
Alvotech$491.95MN/AN/AN/AN/A

Summary

Alvotech beats Jasper Therapeutics on 3 of the 3 factors compared between the two stocks.

How does Jasper Therapeutics compare to Apollomics?

Jasper Therapeutics (NASDAQ:JSPRW) and Apollomics (NASDAQ:APLMW) are both healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their valuation, earnings, dividends, institutional ownership, profitability, analyst recommendations, risk and media sentiment.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Jasper TherapeuticsN/AN/AN/AN/AN/A
Apollomics$8.50MN/AN/AN/AN/A

In the previous week, Jasper Therapeutics' average media sentiment score of 0.00 equaled Apollomics'average media sentiment score.

Company Overall Sentiment
Jasper Therapeutics Neutral
Apollomics Neutral

Company Net Margins Return on Equity Return on Assets
Jasper TherapeuticsN/A N/A N/A
Apollomics N/A N/A N/A

Summary

Apollomics beats Jasper Therapeutics on 1 of the 1 factors compared between the two stocks.

How does Jasper Therapeutics compare to Aravive?

Jasper Therapeutics (NASDAQ:JSPRW) and Aravive (NASDAQ:ARAV) are both healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, valuation, analyst recommendations, institutional ownership, media sentiment, earnings, profitability and dividends.

Company Net Margins Return on Equity Return on Assets
Jasper TherapeuticsN/A N/A N/A
Aravive N/A N/A N/A

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Jasper TherapeuticsN/AN/AN/AN/AN/A
AraviveN/AN/AN/A-$0.90N/A

35.8% of Aravive shares are held by institutional investors. 60.4% of Aravive shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

In the previous week, Jasper Therapeutics' average media sentiment score of 0.00 equaled Aravive'saverage media sentiment score.

Company Overall Sentiment
Jasper Therapeutics Neutral
Aravive Neutral

Summary

Aravive beats Jasper Therapeutics on 2 of the 2 factors compared between the two stocks.

How does Jasper Therapeutics compare to bioAffinity Technologies?

Jasper Therapeutics (NASDAQ:JSPRW) and bioAffinity Technologies (NASDAQ:BIAFW) are both healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their media sentiment, dividends, institutional ownership, earnings, valuation, profitability, analyst recommendations and risk.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Jasper TherapeuticsN/AN/AN/AN/AN/A
bioAffinity Technologies$5.85MN/AN/AN/AN/A

In the previous week, bioAffinity Technologies had 2 more articles in the media than Jasper Therapeutics. MarketBeat recorded 2 mentions for bioAffinity Technologies and 0 mentions for Jasper Therapeutics. Jasper Therapeutics' average media sentiment score of 0.00 beat bioAffinity Technologies' score of -0.66 indicating that Jasper Therapeutics is being referred to more favorably in the media.

Company Overall Sentiment
Jasper Therapeutics Neutral
bioAffinity Technologies Negative

Company Net Margins Return on Equity Return on Assets
Jasper TherapeuticsN/A N/A N/A
bioAffinity Technologies N/A N/A N/A

Summary

bioAffinity Technologies beats Jasper Therapeutics on 2 of the 3 factors compared between the two stocks.

How does Jasper Therapeutics compare to BioVie?

Jasper Therapeutics (NASDAQ:JSPRW) and BioVie (NASDAQ:BIVIW) are both healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, profitability, earnings, analyst recommendations, valuation, institutional ownership, media sentiment and risk.

Company Net Margins Return on Equity Return on Assets
Jasper TherapeuticsN/A N/A N/A
BioVie N/A N/A N/A

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Jasper TherapeuticsN/AN/AN/AN/AN/A
BioVieN/AN/AN/AN/AN/A

In the previous week, BioVie had 1 more articles in the media than Jasper Therapeutics. MarketBeat recorded 1 mentions for BioVie and 0 mentions for Jasper Therapeutics. Jasper Therapeutics' average media sentiment score of 0.00 equaled BioVie'saverage media sentiment score.

Company Overall Sentiment
Jasper Therapeutics Neutral
BioVie Neutral

Summary

BioVie beats Jasper Therapeutics on 1 of the 1 factors compared between the two stocks.

Get Jasper Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for JSPRW and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding JSPRW and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

JSPRW vs. The Competition

Export
MetricJasper TherapeuticsBiotechnology IndustryHealthcare SectorNASDAQ Exchange
Market CapN/A$4.03B$7.26B$12.73B
Dividend YieldN/A3.60%2.53%8.86%
P/E RatioN/A12.66273.2925.25
Price / SalesN/A1,335.53621.7997.64
Price / CashN/A106.8777.8252.26
Price / BookN/A16.8113.086.14
Net IncomeN/A-$22.72M$3.47B$349.01M
7 Day PerformanceN/A0.14%0.52%-0.31%
1 Month PerformanceN/A8.27%5.63%0.64%
1 Year PerformanceN/A52.60%25.31%14.83%

Jasper Therapeutics Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
JSPRW
Jasper Therapeutics
N/A$0.01
+6.5%		N/A-85.8%$0.00N/AN/A20
ALVOW
Alvotech
N/A$0.38
flat		N/A-73.0%$0.00$491.95MN/A4
APLMW
Apollomics
N/A$0.01
-0.7%		N/A+42.3%$0.00$8.50MN/A59
ARAV
Aravive
N/A$0.04
flat		N/AN/A$0.00N/AN/A20
BIAFW
bioAffinity Technologies
N/A$0.13
+78.4%		N/A+1,001.7%$0.00$5.85MN/A10

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:JSPRW) was last updated on 9/4/2026 by MarketBeat.com Staff.
From Our Partners
A Simple Guide to Options Trading While It's Still Free
A free copy of Options Trading Made Simple is available now but wont stay that way for long. Chris Rowe cal...
True Market Insiders | Sponsoredtc pixel
How Long Does $2.5M Last in Retirement?
Having $2.5 million saved puts you ahead of most Americans, but how long it lasts depends on the decisions you...
SmartAsset | Sponsoredtc pixel
Here’s the stock symbol I’ve promised
Whitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...
Stansberry Research | Sponsoredtc pixel
Rickards Predicts: Trump to buy tiny $2 stock?
Jim Rickards believes the Trump administration is about to take a direct stake in a $2 stock sitting on the la...
Paradigm Press | Sponsoredtc pixel
Major Buy Alert Issued for September 30th
Keith Kaplan has invested $17 million into his own AI research tools, building a platform now used by 180,000 ...
TradeSmith | Sponsoredtc pixel
Before Anthropic becomes impossible to ignore...
Riot Platforms just struck a 20-year, 191-megawatt data-center agreement tied to Anthropic, reportedly worth 9...
The Oxford Club | Sponsoredtc pixel
A weekly dividend fund holding Nvidia and Palantir
CrowdStrike, Palantir, Nvidia none of them pay a real dividend. But one fund holding the biggest AI names dist...
Investors Alley | Sponsoredtc pixel
Earth's biggest energy source: near Grand Canyon
The largest energy source on Earth contains 50,000 times every oil and gas reserve on the planet combined - an...
Behind the Markets | Sponsoredtc pixel